Dr. Guild is a board-certified gastroenterologist and a professor at the OU College of Medicine. Dr. Guild sees patients at the Oklahoma City Veterans Affairs Medical Center and at OU Physicians. He has a special interest in diagnosing and treating patients with Gastroesophageal Reflux Disease and Peptic Ulcer Disease. Guild completed a fellowship and residency at the University of Florida after earning his medical degree at the OU College of Medicine.
Academic Section(s):
Digestive Diseases
Education:
University of Oklahoma College of Medicine, Oklahoma City, OK
MD (1974)
Board Certification(s):
American Board of Internal Medicine
Internal Medicine (1977, non-expiring)
American Board of Internal Medicine
Gastroenterology (1981, non-expiring)
Residency:
University of Florida, Gainesville, FL
Internal Medicine (1977)
Fellowship:
University of Florida, Gainesville, FL
Gastroenterology (1981)
Memberships:
American Society for Gastrointestinal Endoscopy, 1989
Arkansas/Oklahoma Endoscopic Society, 1989
American College of Gastroenterology, 1988
Midwest Gut Club, 1988-1999
Oklahoma Society of Parenteral and Enteral Nutrition, 1986-1996
Central Oklahoma Gut Club, 1986
Duval County (Florida) Medical Society (Inactive), 1985-1986
Jacksonville (Florida) Gut Club, 1984-1986
Florida Emergency Medical Services Directors Association, 1984-1986
Florida Gastroenterological Society, 1981-1986
American Gastroenterological Association, 1981
American Society of Parenteral and Enteral Nutrition, 1980-1995
Clinical/Research Interests:
- Colon cancer
- Reflux disease
- Diarrhea
- Constipation
Funding:
Clinical Trials
“A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation”
Co-Principal Investigator
Funding organization: Synergy Pharmaceuticals
Starting date: October 2014
“A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease”
Co-Principal Investigator
Funding Organization: Salix Pharmaceuticals
Starting Date: April 2015
“A Multi-Center, Randomized, Open Label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer® (Ferric Carboxymaltose) vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron Deficiency Anemia(IDA) secondary to Inflammatory Bowel Disease(IBD) or Gastric Bypass.”
Co-Principal Investigator
Funding Organization: Luitpold Pharmaceuticals, Inc.
Starting Date: April 2015
“An Open-Label , Long-Term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)”
Co-Principal Investigator
Funding Organization: Synergy Pharmaceuticals
Starting Date: October 2015
Select Honors & Accomplishments:
- Castle Connolly Medical Ltd. "Top Doctors", 2016-2018
- Fellow, American College of Gastroenterology
Select Publications:
Research Networking Profile